CLINICAL TRIALS PROFILE FOR BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for bupropion hydrochloride; naltrexone hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00129246 ↗ | Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 1/Phase 2 | 2004-12-01 | This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain. |
| NCT00129246 ↗ | Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain | Completed | Yale University | Phase 1/Phase 2 | 2004-12-01 | This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain. |
| NCT00208169 ↗ | Abilify Therapy for Reducing Comorbid Substance Abuse | Completed | Bristol-Myers Squibb | Phase 4 | 2005-03-01 | It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: - Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) - Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale - Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole. |
| NCT00208169 ↗ | Abilify Therapy for Reducing Comorbid Substance Abuse | Completed | Creighton University | Phase 4 | 2005-03-01 | It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: - Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) - Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale - Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole. |
| NCT00364871 ↗ | Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity | Completed | Orexigen Therapeutics, Inc | Phase 2 | 2005-04-01 | The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for bupropion hydrochloride; naltrexone hydrochloride
Condition Name
Clinical Trial Locations for bupropion hydrochloride; naltrexone hydrochloride
Trials by Country
Clinical Trial Progress for bupropion hydrochloride; naltrexone hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for bupropion hydrochloride; naltrexone hydrochloride
Sponsor Name
| Sponsor Name for bupropion hydrochloride; naltrexone hydrochloride | |
| Sponsor | Trials |
| Orexigen Therapeutics, Inc | 15 |
| Yale University | 12 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 6 |
| [disabled in preview] | 8 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
